Business
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification.
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, July 15, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification.","length":473,"tagName":"p"},{"type":"image","alt":"Aethlon Medical, Inc. Logo (PRNewsfoto/Aethlon Medical, Inc.)","displaySize":"","headline":null,"caption":"Aethlon Medical, Inc. Logo (PRNewsfoto/Aethlon Medical, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":138,"url":"https://media.zenfs.com/en/prnewswire.com/c685534e48e0872c689325d5016541a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fXB_Wh9qawQCQGL8_nh7Ww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI0MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c685534e48e0872c689325d5016541a6","width":400,"height":138}},"href":"https://mma.prnewswire.com/media/873016/Aethlon_Medical_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab", is being conducted to assess the Hemopurifier's safety, feasibility, and optimal dosing.","length":322,"tagName":"p"},{"type":"text","content":"The DSMB- comprising independent medical experts in nephrology and oncology- reviewed data from the initial cohort of three participants, each of whom received a single 4-hour Hemopurifier treatment. Based on their evaluation, the board found no safety concerns and confirmed that the Hemopurifier continues to demonstrate a favorable safety and tolerability profile. To date, no serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs) related to the Hemopurifier have been reported.","length":498,"tagName":"p"},{"type":"text","content":""The DSMB's positive recommendation is encouraging and underscores the favorable safety profile observed to date in patients with cancer," according to Steven LaRosa, M.D, Chief Medica...